Article Information
History
- August 17, 2020.
Article Versions
- You are currently viewing Version 1 of this article (August 17, 2020 - 04:46).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Author Information
- Dandan Shan1,†,
- Joseph M Johnson1,†,
- Syrena C. Fernandes1,†,
- Muriel Mendes1,
- Hannah Suib1,
- Marcella Holdridge1,
- Elaine M Burke1,
- Katie Beauregard1,
- Ying Zhang1,
- Megan Cleary1,
- Samantha Xu1,
- Xiao Yao1,
- Purvish P. Patel1,
- Tatiana Plavina1,
- David H. Wilson1,
- Lei Chang1,
- Kim M Kaiser2,
- Jacob Natterman2,3,
- Susanne V Schmidt4,
- Eicke Latz4,5,
- Kevin Hrusovsky1,
- Dawn Mattoon1 and
- Andrew J. Ball1,*
- 1Quanterix Corporation, Billerica, MA 01821, USA
- 2Institute of Innate Immunity, University of Bonn, Bonn, Germany
- 3German Center for Infection Research (DZIF), Bonn, Germany
- 4Department of Internal Medicine I, University of Bonn, Bonn, Germany
- 5German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
- ↵*Correspondence to: aball{at}quanterix.com
↵† These authors contributed equally
Posted August 17, 2020.
SARS-Coronavirus-2 nucleocapsid protein measured in blood using a Simoa ultra-sensitive immunoassay differentiates COVID-19 infection with high clinical sensitivity
